Medpace Holdings, Inc.
Financials
Valuation Metrics
Medpace Holdings, Inc.'s Market Cap is $18.08B. At end of 2025 it was $15.89B. Ranked #622 of 3,118 in US market (top 20%), #191 of 1,474 on NASDAQ (top 13%), #44 of 203 in Health Care Equipment & Services (top 22%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $18.08B | US#622/3,118 Sec#44/203 |
| Revenue | $2.84B | US#1,222/3,118 Sec#76/203 |
| Net Income | $518M | US#829/3,118 Sec#48/203 |
| Total Assets | $2.30B | US#1,988/3,118 Sec#98/203 |
| Net Assets | $585M | US#2,111/3,118 Sec#109/203 |
| Employees | 6,200 | US#1,100/3,118 Sec#82/203 |
| Value | ||
| P/E | 34.92x | US#1,716/3,118 Sec#71/203 |
| P/B | 30.91x | US#2,852/3,118 Sec#186/203 |
| PEG | 1.78x | US#1,007/3,118 Sec#49/203 |
| P/S | 6.37x | US#2,478/3,118 Sec#162/203 |
| EV/EBITDA | 27.23x | US#2,155/3,118 Sec#110/203 |
| FCF Yield | 3.69% | US#1,670/3,118 Sec#88/203 |
| Profitability | ||
| ROE | 88.53% | US#36/3,118 Sec#3/203 |
| ROA | 22.49% | US#89/3,118 Sec#3/203 |
| Op. Margin | 21.39% | US#821/3,118 Sec#24/203 |
| Revenue Growth | 20.35% | US#672/3,118 Sec#41/203 |
| Earnings Growth | 19.59% | US#857/3,118 Sec#47/203 |
| Financial Health | ||
| Debt Ratio | 293.65% | US#2,085/3,118 Sec#171/203 |
| Total Debt | $146M | US#2,329/3,118 Sec#130/203 |
| FCF | $668M | US#762/3,118 Sec#46/203 |
| Cash | $705M | US#865/3,118 Sec#47/203 |
| Current Ratio | 0.83x | US#2,459/3,118 Sec#198/203 |
| Net Debt/EBITDA | -0.87x | US#311/3,118 Sec#26/203 |
| Performance | ||
| 1Y Return | 10.77% | US#1,412/3,118 Sec#107/203 |
| 1M Return | 8.08% | US#1,303/3,118 Sec#110/203 |
| From 52W High | -6.64% | US#508/3,118 Sec#49/203 |
| 1Y MDD | -36.61% | US#1,737/3,118 Sec#105/203 |
| Trading | ||
| Volume | 163,192 shares | US#2,733/3,118 Sec#186/203 |
| Trading Value | $106M | US#862/3,118 Sec#67/203 |
| Per Share | ||
| EPS | $18.55 | US#102/3,118 Sec#11/203 |
| BPS | $20.96 | US#1,189/3,118 Sec#67/203 |
Company Info
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.